Scholarlink

Objective <p>To evaluate the safety and efficacy of postnatal magnesium sulfate (MgSO₄) for neuroprotection in neonates with neonatal encephalopathy (NE).</p> Study design <p>Systematic review and meta-analysis of controlled clinical trials assessing MgSO₄ administered within 12 h of birth in term or near-term infants with NE. Databases searched included MEDLINE, Embase, and Cochrane sources.</p> Results <p>Twenty-four trials were included. MgSO₄ was consistently safe, with no significant adverse hemodynamic or respiratory effects. Meta-analyses demonstrated improved short-term outcomes, including reduced seizure occurrence, improved neurological status at discharge, and earlier establishment of feeding. No significant reduction in mortality was observed. Evidence regarding long-term neurodevelopmental outcomes was extremely limited. Most pre-therapeutic hypothermia studies demonstrated favorable short-term neurological or clinical outcomes. Studies conducted alongside therapeutic hypothermia have not reported long-term outcomes.</p> Conclusion <p>Postnatal MgSO₄ is safe and associated with improved short-term clinical outcomes in neonates with NE. However, absence of long-term benefit and limited evidence in the era of therapeutic hypothermia preclude routine clinical use.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Magnesium sulfate for brain protection in neonatal encephalopathy: a systematic review

  • 期刊论文

  • 发表日期：

    2026年7月27日

查看全文
  • Francis B. Mimouni,
  • Yuval Dadon,
  • Iris Arad,
  • Joseph Mendlovic

摘要

Objective

To evaluate the safety and efficacy of postnatal magnesium sulfate (MgSO₄) for neuroprotection in neonates with neonatal encephalopathy (NE).

Study design

Systematic review and meta-analysis of controlled clinical trials assessing MgSO₄ administered within 12 h of birth in term or near-term infants with NE. Databases searched included MEDLINE, Embase, and Cochrane sources.

Results

Twenty-four trials were included. MgSO₄ was consistently safe, with no significant adverse hemodynamic or respiratory effects. Meta-analyses demonstrated improved short-term outcomes, including reduced seizure occurrence, improved neurological status at discharge, and earlier establishment of feeding. No significant reduction in mortality was observed. Evidence regarding long-term neurodevelopmental outcomes was extremely limited. Most pre-therapeutic hypothermia studies demonstrated favorable short-term neurological or clinical outcomes. Studies conducted alongside therapeutic hypothermia have not reported long-term outcomes.

Conclusion

Postnatal MgSO₄ is safe and associated with improved short-term clinical outcomes in neonates with NE. However, absence of long-term benefit and limited evidence in the era of therapeutic hypothermia preclude routine clinical use.